Free Trial

Medicis Pharmaceutical (MRX) Stock Forecast & Price Target

Notice: This company has been marked as potentially delisted and may not be actively trading.

Medicis Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 7 Analyst Ratings

Consensus Price Target

$26.29
26.25% Upside
High Forecast$33.00
Average Forecast$26.29
Low Forecast$24.00
TypeCurrent Forecast
5/23/23 to 5/22/24
1 Month Ago
4/23/23 to 4/22/24
3 Months Ago
2/22/23 to 2/22/24
1 Year Ago
5/23/22 to 5/23/23
Consensus Rating
Buy
N/AN/AN/A
Strong Buy
0 Strong Buy rating(s)
N/A N/A N/A
Buy
7 Buy rating(s)
N/A N/A N/A
Hold
0 Hold rating(s)
N/A N/A N/A
Sell
0 Sell rating(s)
N/A N/A N/A
Consensus Price Target$26.29N/AN/AN/A
Forecasted Upside26.25% UpsideN/AN/AN/A
Get Medicis Pharmaceutical Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MRX and its competitors with MarketBeat's FREE daily newsletter.

MRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Medicis Pharmaceutical Stock vs. The Competition

TypeMedicis PharmaceuticalFinance CompaniesS&P 500
Consensus Rating Score
3.00
2.44
2.49
Consensus RatingBuyHoldHold
Predicted Upside26.25% Upside56.82% Upside8.37% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/20/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$33.00+72.96%
5/20/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$25.00+31.03%
5/20/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Moley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$27.00+41.51%
5/20/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$27.00+41.51%
5/20/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$24.00+25.79%
5/20/2024Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Voigt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$24.00+25.79%
5/20/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$24.00+25.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:51 AM ET.

MRX Frequently Asked Questions

What is Medicis Pharmaceutical's stock forecast and purchase recommendation?

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Medicis Pharmaceutical is $26.29, with a high forecast of $33.00 and a low forecast of $24.00. The consensus rating for Medicis Pharmaceutical stock is Buy based on the current 7 buy ratings for MRX. Learn more on MRX's analyst rating history.

Do Wall Street analysts like Medicis Pharmaceutical more than its competitors?

Analysts like Medicis Pharmaceutical more than other "finance" companies. The consensus rating for Medicis Pharmaceutical is Buy while the average consensus rating for "finance" companies is Hold. Learn more on how MRX compares to other companies.

Does Medicis Pharmaceutical's stock price have much upside?

According to analysts, Medicis Pharmaceutical's stock has a predicted upside of 37.77% based on their 12-month stock forecasts.

What analysts cover Medicis Pharmaceutical?

Medicis Pharmaceutical has been rated by research analysts at Barclays, Citigroup, Jefferies Financial Group, Keefe, Bruyette & Woods, Piper Sandler, The Goldman Sachs Group, and UBS Group in the past 90 days.


Stock Forecasts and Research Tools

This page (NYSE:MRX) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners